Research platforms

The agency supports a number of national and international research platforms in a variety of fields, covering the entire continuum of infectious disease research. The research platforms presented here do not represent an exhaustive overview.

Last updated on 12 September 2025

In brief

These platforms are designed to provide scientific communities with access to specific technologies, equipment, devices, tools and expertise to answer scientific  and major societal challenges in healthcare, in particular the elimination of HIV/AIDS, sexually-transmitted infections, viral hepatitis and tuberculosis, as well as the prevention, detection and control of emerging infectious diseases.

Genomic surveillance platforms

The development of genomic surveillance networks is emerging as a strategic lever for better understanding the characteristics of pathogens and their variants, and for guiding the health response.


EMERGEN 2.0 Consortium

In 2025, EMERGEN becomes EMERGEN 2.0, broadening its scope to include other emerging pathogens. The consortium also affirms its One Health approach with the addition of Anses to its coordination team.

AFROSCREEN

The AFROSCREEN project aims to establish a genomic surveillance network that helps build laboratory capacity for the diagnosis, detection and surveillance of SARS-CoV-2 variants and other emerging pathogens.

Clinical platforms

The aim is to consolidate existing research infrastructure in order to strengthen France’s capacity to respond quickly and effectively to new emergencies, particularly in the areas of clinical and vaccine research


Open ReMIE: A national platform for research

Launched in 2025, Open-ReMIE is a national platform dedicated to therapeutic clinical research on emerging infectious diseases in France led by ANRS MIE and co-led by Hospices Civils de Lyon.

I-REIVAC Emergence

I-REIVAC Emergence is a national clinical vaccine research platform against emerging infectious diseases. Jointly led by Inserm / ANRS Emerging Infectious Diseases (ANRS MIE) and the Paris Public Hospitals Group (AP-HP), I-REIVAC was developed during the COVID-19 pandemic.

Strive: An international network of clinical trials

Strive is an international network of clinical trials on infectious respiratory threats and viral emergences funded by the National Institutes of Health (NIH).